Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Metagenomi Therapeutics, Inc.Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare ConferenceMetagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a panel discussion titled “Genome Editing: Next-Wave Platforms Beyond CRISPR 1.0” at the Chardan 10th Annual Healthcare Conference on Tuesday, October 20, 2026, at 10:30 a.m. ET, being held in New York, NY.
- aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological ChemistryaTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
- Envisagenics Awarded $2M+ NCI SBIR Grant to Expand AI-Driven RNA Splicing Analysis Capabilities Across Oncology PortfolioFunding will advance translational readiness across Envisagenics’ cancer-specific programs for internal development and strategic partnering
- TaiMed BiologicsTaiMed Biologics to Present Oral and Poster Presentations on TMB-365 and TMB-365/TMB-380 Combination Therapy at IDWeek 2026Company will present on a single-dose escalation study of TMB-365 and on resistance in the context of the long-acting TMB-365 and TMB-380 maintenance regimen in people living with HIV
- IFx 2.0 Market Size and Sales Forecast in the 7MM - 2034 | Phase III Momentum and Checkpoint Inhibitor Combinations Expand Commercial PotentialLate-stage development, KEYTRUDA combination potential, orphan drug advantages and multiple tumor expansion position IFx-2.0 for faster adoption and portfolio returns.
- Sibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to ClinicSibylla Biotech today announced key executive appointments, including Usman Azam, MD, as Chief Executive Officer and Gianluca Fuggetta, MSc, MBA, as Chief Financial Officer. Both bring significant international corporate expertise, with Dr. Azam contributing more than 25 years of global biopharmaceutical executive, scientific and clinical development leadership. Co-founder and previous CEO Lidia Pieri, PhD, MBA, will remain with the company in the role of Chief Operating Officer. Sibylla also announced the promotion of Elena Ardini, MSc, from Vice President, Research and Development to Chief Scientific Officer. The executive leadership team expansion highlights the company’s progress in validating its differentiated folding interference protein degradation technology and its commitment to bringing its lead program into clinical evaluation.
- Zelluna ASA: Invitation to Third Quarter 2026 Results Webcast Including ZIMA-101 Clinical Progress UpdateOslo, 13 October 2026 – Zelluna (OSE: ZLNA), a clinical-stage biotechnology Company pioneering allogeneic, off-the-shelf T-cell receptor-based natural killer (TCR-NK) cell therapies for solid cancers, will publish its financial results for the third quarter of 2026 on Thursday, 5 November 2026.
- Akiram TherapeuticsAkiram Therapeutics: First clinical results from AKIR001 to be presented at EANM 2026Akiram Therapeutics, a Swedish clinical-stage biotech company specializing in molecular radiotherapy, announces that the first clinical data from the ongoing Phase I trial of its lead drug candidate 177Lu-AKIR001 will be presented at the EANM 2026 Congress in Vienna, October 17-21....
- HmediumFrost & Sullivan Released the 2026 Global Gene Therapy Industry Development Blue BookFrost & Sullivan officially released the 2026 Global Gene Therapy Industry Development Blue Book in October 2026, in collaboration with industry partners. The report systematically examines the industry's development history, core technology classifications, policy and capital market dynamics, upstream and downstream value chains, bottlenecks in viral vector manufacturing, clinical progress across key indications, reimbursement pathways, and...
- LabConnectGCCL and LabConnect Sign MOU to Expand Global Clinical Trial CollaborationLinking North American and Asia-Pacific Capabilities to Support Joint Sales and Project Execution — GCCL, a South Korea-based leading global clinical trial central laboratory represented by CEO Kwan-goo Cho, announced today...
- Teva Pharmaceutical Industries LtdTeva to Host R&D Day on Wednesday, November 11 in New York CityTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D Day, Teva’s leadership will discuss its R&D pipeline, its near-term value-creation potential over the next five years, and Teva’s ongoing transformation into an innovative biopharma company through the Pivot to Growth strategy.
- M&A Healthcare Advisors LLCM&A Healthcare Advisors Advises Innovo Detox on Sale to R&S Holdings, Inc.M&A Healthcare Advisors (MAHA), a FINRA-licensed investment bank focused on the healthcare industry, is pleased to announce the sale of Innovo Detox (Innovo), a Pennsylvania-based provider of substance use disorder (SUD) treatment and drug and...